CONTEXT: Antibiotic prescription in hospice patients is complicated by the focus on palliative rather than curative care and concerns regarding increasing antibiotic resistance. OBJECTIVES: To estimate the antibiotic use in a national sample of hospice patients and identify facility and patient characteristics associated with antibiotic use in this population. METHODS: This was an analysis of data from the 2007 National Home and Hospice Care Survey, a nationally representative sample of U.S. hospice agencies. We included data from 3884 patients who died in hospice care. The primary outcome measure was prevalence of antibiotic use in the last seven days of life. Diagnoses, including potential infectious indications for antibiotic use, were defined using International Classification of Diseases, Ninth Revision (ICD-9) codes. Chi-squared tests and t-tests were used to quantify associations of patient and facility characteristics with antibiotic use. RESULTS: During the last seven days of life, 27% (95% CI: 24%-30%) of patients received at least one antibiotic and 1.3% (95% CI: 0.7%-2.0%) received three or more antibiotics. Among patients who received at least one antibiotic, 15% (95% CI: 10%-20%) had a documented infectious diagnosis compared with 9% (95% CI: 7%-11%), who had an infectious diagnosis but received no antibiotics. CONCLUSION: In this nationally representative sample, 27% of hospice patients received an antibiotic during the last seven days of life, most without a documented infectious diagnosis. Further research is needed to elucidate the role of antibiotics in this patient population to maintain palliative care goals while reducing unnecessary antibiotic use.
CONTEXT: Antibiotic prescription in hospice patients is complicated by the focus on palliative rather than curative care and concerns regarding increasing antibiotic resistance. OBJECTIVES: To estimate the antibiotic use in a national sample of hospice patients and identify facility and patient characteristics associated with antibiotic use in this population. METHODS: This was an analysis of data from the 2007 National Home and Hospice Care Survey, a nationally representative sample of U.S. hospice agencies. We included data from 3884 patients who died in hospice care. The primary outcome measure was prevalence of antibiotic use in the last seven days of life. Diagnoses, including potential infectious indications for antibiotic use, were defined using International Classification of Diseases, Ninth Revision (ICD-9) codes. Chi-squared tests and t-tests were used to quantify associations of patient and facility characteristics with antibiotic use. RESULTS: During the last seven days of life, 27% (95% CI: 24%-30%) of patients received at least one antibiotic and 1.3% (95% CI: 0.7%-2.0%) received three or more antibiotics. Among patients who received at least one antibiotic, 15% (95% CI: 10%-20%) had a documented infectious diagnosis compared with 9% (95% CI: 7%-11%), who had an infectious diagnosis but received no antibiotics. CONCLUSION: In this nationally representative sample, 27% of hospice patients received an antibiotic during the last seven days of life, most without a documented infectious diagnosis. Further research is needed to elucidate the role of antibiotics in this patient population to maintain palliative care goals while reducing unnecessary antibiotic use.
Authors: Stephanie Stiel; Norbert Krumm; Martina Pestinger; Gabriele Lindena; Friedemann Nauck; Christoph Ostgathe; Lukas Radbruch; Frank Elsner Journal: Support Care Cancer Date: 2011-01-28 Impact factor: 3.603
Authors: Patrick H White; Heather L Kuhlenschmidt; Benjamin G Vancura; Rudolph M Navari Journal: J Pain Symptom Manage Date: 2003-05 Impact factor: 3.612
Authors: Jen-Hau Chen; Jennifer L Lamberg; Yen-Ching Chen; Dan K Kiely; John H Page; Carmel J Person; Susan L Mitchell Journal: J Am Geriatr Soc Date: 2006-02 Impact factor: 5.562
Authors: Joseph H Rosenberg; Jennifer S Albrecht; Erik K Fromme; Brie N Noble; Jessina C McGregor; Angela C Comer; Jon P Furuno Journal: J Palliat Med Date: 2013-10-23 Impact factor: 2.947
Authors: Jon P Furuno; Brie N Noble; Kristi N Horne; Jessina C McGregor; Miriam R Elman; David T Bearden; Eric W Walsh; Erik K Fromme Journal: Antimicrob Agents Chemother Date: 2014-07-07 Impact factor: 5.191
Authors: Maria Sercu; Veerle Van Renterghem; Peter Pype; Karolien Aelbrecht; Anselme Derese; Myriam Deveugele Journal: Scand J Prim Health Care Date: 2015-12-10 Impact factor: 2.581